TY - JOUR
T1 - Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver
AU - Gray, Michael J.
AU - Van Buren, George
AU - Dallas, Nikolaos A.
AU - Xia, Ling
AU - Wang, Xuemei
AU - Yang, Anthony D.
AU - Somcio, Ray J.
AU - Lin, Yvonne G.
AU - Lim, Sherry
AU - Fan, Fan
AU - Mangala, Lingegowda S.
AU - Arumugam, Thiruvengadam
AU - Logsdon, Craig D.
AU - Lopez-Berestein, Gabriel
AU - Sood, Anil K.
AU - Ellis, Lee M.
N1 - Funding Information:
National Institute of Health -5 T32 CA09599 (to G. V. Buren, N. A. Dallas, A. D. Yang, and S. Lim); Program Project Development Grant from the Ovarian Cancer Research Fund, Inc. (to A. K. Sood); the Zarrow Foundation (to A. K. Sood); The John E. and Dorothy Harris Fund for Gastrointestinal Cancer Research (to L. M. Ellis); The William C. Liedtke, Jr, Fund for Cancer Research (to L. M. Ellis); National Institutes of Health (RO1 CA112390 to L. M. Ellis).
PY - 2008/1
Y1 - 2008/1
N2 - Background: Neuropilin-2 (NRP2) is a high-affinity kinase-deficient receptor for vascular endothelial growth factor (VEGF) and semaphorin 3F. We investigated its function in human colorectal cancers. Methods: Immunohistochemistry and immunoblotting were used to assess NRP2 expression levels in colorectal tumors and colorectal cancer cell lines, respectively. HCT-116 colorectal cancer cells stably transfected with short hairpin RNA (shRNAs) against NRP2 or control shRNAs were assayed for proliferation by the tetrazolium salt 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and for activation of the VEGFR1 pathway by immunoblotting. Soft agar assays, Annexin V staining, and Boyden chamber assays were used to examine anchorage-independent growth, apoptosis in response to hypoxia, and cell migration/invasion, respectively, in HCT-116 transfectants. Tumor growth and metastasis were analyzed in mice (groups of 10) injected with shRNA-expressing HCT-116 cells. The effect of in vivo targeting of NRP2 by small interfering RNA (siRNA) on the growth of hepatic colorectal tumors derived from luciferase-expressing HCT-116 cells was assessed by measuring changes in bioluminescence and final tumor volumes. All statistical tests were two-sided. Results: NRP2 expression was substantially higher in tumors than in adjacent mucosa. HCT-116 transfectants with reduced NRP2 levels had reduced VEGFR1 signaling, but proliferation was unchanged. Anchorage-independent growth, survival under hypoxic conditions, and motility/invasiveness were also reduced. In vivo, HCT-116 transfectants with reduced NRP2 demonstrated decreased tumor growth, fewer metastases, and increased apoptosis compared with control cells. Hepatic colorectal tumors in mice treated with NRP2 siRNAs were statistically significantly smaller than those in mice treated with control siRNAs (at 28 days after implantation, mean control siRNAs = 420 mm3, mean NRP2 siRNAs = 36 mm3, NRP2 vs control: difference = 385 mm3, 95% confidence interval = 174 mm3 to 595 mm3, P =. 005). Conclusion: NRP2 on colorectal carcinoma cells is important for tumor growth and is a potential therapeutic target in human cancers where it is expressed.
AB - Background: Neuropilin-2 (NRP2) is a high-affinity kinase-deficient receptor for vascular endothelial growth factor (VEGF) and semaphorin 3F. We investigated its function in human colorectal cancers. Methods: Immunohistochemistry and immunoblotting were used to assess NRP2 expression levels in colorectal tumors and colorectal cancer cell lines, respectively. HCT-116 colorectal cancer cells stably transfected with short hairpin RNA (shRNAs) against NRP2 or control shRNAs were assayed for proliferation by the tetrazolium salt 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and for activation of the VEGFR1 pathway by immunoblotting. Soft agar assays, Annexin V staining, and Boyden chamber assays were used to examine anchorage-independent growth, apoptosis in response to hypoxia, and cell migration/invasion, respectively, in HCT-116 transfectants. Tumor growth and metastasis were analyzed in mice (groups of 10) injected with shRNA-expressing HCT-116 cells. The effect of in vivo targeting of NRP2 by small interfering RNA (siRNA) on the growth of hepatic colorectal tumors derived from luciferase-expressing HCT-116 cells was assessed by measuring changes in bioluminescence and final tumor volumes. All statistical tests were two-sided. Results: NRP2 expression was substantially higher in tumors than in adjacent mucosa. HCT-116 transfectants with reduced NRP2 levels had reduced VEGFR1 signaling, but proliferation was unchanged. Anchorage-independent growth, survival under hypoxic conditions, and motility/invasiveness were also reduced. In vivo, HCT-116 transfectants with reduced NRP2 demonstrated decreased tumor growth, fewer metastases, and increased apoptosis compared with control cells. Hepatic colorectal tumors in mice treated with NRP2 siRNAs were statistically significantly smaller than those in mice treated with control siRNAs (at 28 days after implantation, mean control siRNAs = 420 mm3, mean NRP2 siRNAs = 36 mm3, NRP2 vs control: difference = 385 mm3, 95% confidence interval = 174 mm3 to 595 mm3, P =. 005). Conclusion: NRP2 on colorectal carcinoma cells is important for tumor growth and is a potential therapeutic target in human cancers where it is expressed.
UR - http://www.scopus.com/inward/record.url?scp=38449095310&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=38449095310&partnerID=8YFLogxK
U2 - 10.1093/jnci/djm279
DO - 10.1093/jnci/djm279
M3 - Article
C2 - 18182619
AN - SCOPUS:38449095310
SN - 0027-8874
VL - 100
SP - 109
EP - 120
JO - Journal of the National Cancer Institute
JF - Journal of the National Cancer Institute
IS - 2
ER -
